☆ 4.5 Letter

High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease

ANNALS OF HEMATOLOGY (2019)

Journal

ANNALS OF HEMATOLOGY

Volume 98, Issue 4, Pages 1031-1032

Publisher

SPRINGER

DOI: 10.1007/s00277-018-3521-4

Keywords

-

Categories

Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Biotechnology & Applied Microbiology

Monoclonal antibodies for treatment of cold agglutinin disease

Georg Gelbenegger, Sigbjorn Berentsen, Bernd Jilma

Summary: Cold agglutinin disease (CAD) is a difficult-to-treat autoimmune hemolytic anemia and B cell lymphoproliferative disorder. This review summarizes clinical and experimental antibody-based treatments for CAD and discusses potential future treatments for CAD.

EXPERT OPINION ON BIOLOGICAL THERAPY (2023)

Add to Collection

Article Education, Scientific Disciplines

Cold AIHA and the best treatment strategies

Jenny McDade Despotovic, Taylor Olmsted Kim

Summary: Cold reactive autoimmune hemolytic anemia is a rare condition caused by the production of autoantibodies against endogenous red blood cells. Treatment mainly focuses on reducing antibody production to manage the disease.

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2022)

Add to Collection

Review Pharmacology & Pharmacy

Development of New Drugs for Autoimmune Hemolytic Anemia

Zhengrui Xiao, Irina Murakhovskaya

Summary: AIHA is a rare autoimmune disorder characterized by the destruction of red blood cells mediated by autoantibodies, presenting challenges in treatment. Traditional first-line therapies have associated adverse effects and treatment failures, with high rates of relapse. Some patients are refractory to available treatments, leading to the importance of novel therapies.

PHARMACEUTICS (2022)

Add to Collection

Review Medicine, Research & Experimental

Practical therapy for primary autoimmune hemolytic anemia in adults

Maria Celeste Fatone, Lorenzo Cirasino

Summary: This article provides a practical guide for the therapy of autoimmune hemolytic anemias (AIHA) and discusses the different treatment approaches for primary warm AIHA and AIHA from cold agglutinin disease (AIHA from CAD). The article emphasizes the importance of identifying the type of antibody involved in the disease and excluding a secondary form. Rituximab is highlighted as a central treatment for primary warm AIHA and AIHA from CAD.

CLINICAL AND EXPERIMENTAL MEDICINE (2023)

Add to Collection

Review Hematology

Sutimlimab for the Treatment of Cold Agglutinin Disease

Sigbjorn Berentsen

Summary: Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia and a bone marrow clonal lymphoproliferative disorder. Hemolysis in CAD is complement-dependent and mediated by the classical activation pathway. Sutimlimab, a humanized monoclonal IgG4 antibody, is the most extensively investigated complement inhibitor for the treatment of CAD. It has been proven to be highly efficacious with low toxicity in clinical trials and is approved for CAD treatment in multiple countries.

HEMASPHERE (2023)

Add to Collection

Article Immunology

Sutimlimab for treatment of cold agglutinin disease: why, how and for whom?

Sigbjorn Berentsen, Wilma Barcellini, Shirley D'Sa, Bernd Jilma

Summary: Sutimlimab, the first complement inhibitor to be extensively studied in cold agglutinin disease, has shown high response rates with low toxicity. The drug appears highly useful in severely anemic patients and in those in whom chemoimmunotherapy is contraindicated or has failed. The choice of therapy in cold agglutinin disease should be individualized.

IMMUNOTHERAPY (2022)

Add to Collection

Review Pathology

The Histopathology of Cold Agglutinin Disease-Associated B-Cell Lymphoproliferative Disease

Angela Guenther, Anne Tierens, Agnieszka Malecka, Jan Delabie

Summary: Primary cold agglutinin disease is a type of autoimmune hemolytic anemia caused by circulating antibodies against I antigen. It has been recognized as a distinct B-cell lymphoproliferative disease and has been included in the most recent classifications of mature B-cell neoplasms.

AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2023)

Add to Collection

Review Hematology

Sutimlimab for the Treatment of Cold Agglutinin Disease

Sigbjorn Berentsen

Summary: Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia caused by complement-dependent hemolysis. Sutimlimab, a humanized monoclonal IgG4 antibody that inhibits complement protein C1s, has been proven to be a highly effective and low-toxic treatment for CAD. However, it does not improve cold-induced circulatory symptoms. Individual assessment and consideration for inclusion in clinical trials should guide the choice of therapy for CAD.

HEMASPHERE (2023)

Add to Collection

Article Medicine, General & Internal

Hemolytic Anemia in the Setting of Atypical Pneumonia: A Case of Cold Agglutinin Disease

Abdelwahab Jalal Eldin, Roshni Thomas, Gary Gibson, Davis Abongwa, Israa Hassan, Mpey K. Tabot Tabot, Gagan Singh, Ravi Sarma

Summary: This is a case of secondary cold agglutinin hemolytic anemia in a 23-year-old female. It highlights the importance of considering secondary cAHA in patients with cold symptoms or unexplained hemolysis.

CUREUS JOURNAL OF MEDICAL SCIENCE (2023)

Add to Collection

Review Hematology

Current Treatment Options in Cold Agglutinin Disease: B-Cell Directed or Complement Directed Therapy?

Sigbjorn Berentsen, Geir E. Tjonnfjord

Summary: Cold agglutinin disease can be treated through targeted therapies focusing on clonal B-cell lymphoproliferation and complement-mediated hemolysis. Bendamustine plus rituximab combination and sutimlimab have shown success in treating the disease. Bendamustine-rituximab is effective but slow-acting, while sutimlimab is highly efficacious and acts rapidly with low toxicity.

TRANSFUSION MEDICINE REVIEWS (2022)

Add to Collection

Review Immunology

Severe autoimmune hemolytic anemia; epidemiology, clinical management, outcomes and knowledge gaps

Femke V. M. Mulder, Dorothea Evers, Masja de Haas, Marjan J. Cruijsen, Sophie J. Bernelot Moens, Wilma Barcellini, Bruno Fattizzo, Josephine M. I. Vos

Summary: This article discusses severe autoimmune hemolytic anemia (AIHA), including its definition, understanding of severity and prognosis. Though there are no validated predictors for severe disease course, certain risk factors can aid in identifying severe cases. Certain serological subtypes are associated with lower hemoglobin levels, higher transfusion need and mortality. Currently, there is no evidence-based therapeutic approach, but there are general management strategies and emerging therapeutic options. Further research and development of prediction models and new drugs are needed in the future.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Review Pharmacology & Pharmacy

Sutimlimab: A Complement C1s Inhibitor for the Management of Cold Agglutinin Disease-Associated Hemolysis

Donald C. Moore, Justin R. Arnall

Summary: Sutimlimab, a first-in-class complement C1s inhibitor, is an effective therapeutic option for the management of CAD-associated hemolysis. It rapidly improves hemoglobin levels and symptoms. However, safety concerns include infusion-related reactions and the risk of infections.

ANNALS OF PHARMACOTHERAPY (2023)

Add to Collection

Article Hematology

Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia in Association with Antiphospholipid Syndrome

Ram Gelman, Fadi Kharouf, Yuval Ishay, Alexander Gural

Summary: Antiphospholipid syndrome and cold agglutinin-mediated autoimmune hemolytic anemia are two distinct immune-mediated hematologic disorders, and while no clear association exists between them, complement activation is known to occur in both cases.

ACTA HAEMATOLOGICA (2021)

Add to Collection

Article Immunology

A New Murine Model of Primary Autoimmune Hemolytic Anemia (AIHA)

Flavia Dei Zotti, Annie Qiu, Francesca La Carpia, Chiara Moriconi, Krystalyn E. Hudson

Summary: Autoimmune hemolytic anemia is a severe disease with limited treatment options and challenges in RBC transfusions due to autoantibodies against ubiquitous RBC antigens.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Review Hematology

Clinical and epidemiological features of paroxysmal cold hemoglobinuria: a systematic review

Jeremy W. Jacobs, Cristina A. Figueroa Villalba, Garrett S. Booth, Jennifer S. Woo, Laura D. Stephens, Brian D. Adkins

Summary: Paroxysmal cold hemoglobinuria (PCH) is a rare autoimmune hemolytic anemia that is often overlooked and challenging to diagnose due to the complicated testing methods required. A systematic review of reported cases revealed that PCH most commonly occurs in children with a preceding viral infection, and corticosteroid use is frequent but potentially ineffective. The presence of complement and absence of IgG bound to red blood cells is the most common DAT result, although other findings were observed in a third of cases.

BLOOD ADVANCES (2023)

Add to Collection

Article Biochemical Research Methods

A simple HPLC assay for determining eltrombopag concentration in human serum

Naoya Yanagimachi, Naoshi Obara, Mamiko Sakata-Yanagimoto, Shigeru Chiba, Kosuke Doki, Masato Homma

Summary: An HPLC assay was developed to determine serum eltrombopag concentration in ITP patients, showing high recovery rates and precision. The method could be used for therapeutic drug monitoring of eltrombopag in ITP patients.

BIOMEDICAL CHROMATOGRAPHY (2021)

Add to Collection

Letter Oncology

Intratumor heterogeneity of lymphoma identified by multiregion sequencing of autopsy samples

Kenichi Makishima, Yasuhito Suehara, Yoshiaki Abe, Keiichiro Hattori, Manabu Kusakabe, Ryota Matsuoka, Shigeru Chiba, Mamiko Sakata-Yanagimoto

CANCER SCIENCE (2022)

Add to Collection

Article Medicine, General & Internal

Salvage Cord Blood Transplantation Using a Short-term Reduced-intensity Conditioning Regimen for Graft Failure

Sakurako Suma, Yasuhisa Yokoyama, Haruka Momose, Kenichi Makishima, Yusuke Kiyoki, Tatsuhiro Sakamoto, Manabu Kusakabe, Takayasu Kato, Naoki Kurita, Hidekazu Nishikii, Mamiko Sakata-Yanagimoto, Naoshi Obara, Yuichi Hasegawa, Shigeru Chiba

Summary: Cord blood transplantation with a fixed dose of fludarabine may be a promising salvage therapy for graft failure, leading to successful hematopoietic recovery.

INTERNAL MEDICINE (2022)

Add to Collection

Article Cell Biology

A single-cell atlas of non-haematopoietic cells in human lymph nodes and lymphoma reveals a landscape of stromal remodelling

Yoshiaki Abe, Mamiko Sakata-Yanagimoto, Manabu Fujisawa, Hiroaki Miyoshi, Yasuhito Suehara, Keiichiro Hattori, Manabu Kusakabe, Tatsuhiro Sakamoto, Hidekazu Nishikii, Tran B. Nguyen, Yohei Owada, Tsuyoshi Enomoto, Aya Sawa, Hiroko Bando, Chikashi Yoshida, Rikako Tabata, Toshiki Terao, Masahiro Nakayama, Koichi Ohshima, Kensuke Usuki, Tatsuya Oda, Kosei Matsue, Shigeru Chiba

Summary: This study constructed a single-cell transcriptome atlas of non-haematopoietic cells (NHCs), including mesenchymal stromal cells and endothelial cells, collected from human samples. The atlas revealed 30 distinct subclusters of NHCs, including previously unrecognized ones. Comparative analyses with lymphoma NHCs showed subcluster-specific changes in gene expression and interaction with malignant cells in follicular lymphoma NHCs, providing insights into stromal remodelling in lymphoma and potential clinical biomarkers. The study updates NHC taxonomy in human lymph nodes and provides a rich resource for advancing lymphoma management and therapy.

NATURE CELL BIOLOGY (2022)

Add to Collection

Article Hematology

Clonal germinal center B cells function as a niche for T-cell lymphoma

Manabu Fujisawa, Tran B. Nguyen, Yoshiaki Abe, Yasuhito Suehara, Kota Fukumoto, Sakurako Suma, Kenichi Makishima, Chihiro Kaneko, Yen T. M. Nguyen, Kensuke Usuki, Kentaro Narita, Kosei Matsue, Naoya Nakamura, Shumpei Ishikawa, Fumihito Miura, Takashi Ito, Ayako Suzuki, Yutaka Suzuki, Seiya Mizuno, Satoru Takahashi, Shigeru Chiba, Mamiko Sakata-Yanagimoto

Summary: This study investigates the mechanism by which TET2-mutant immune cells enable the development of Angioimmunoblastic T-cell lymphoma (AITL). The results reveal that Tet2-deficient immune cells play a crucial role in AITL development, and aberrant GCB cells in AITL undergo clonal evolution with recurrent mutations in genes related to core histones. Cd40-Cd40lg is identified as a possible mediator of interactions between GCB and tumor cell clusters.

BLOOD (2022)

Add to Collection

Article Hematology

Hemolysis induced by SARS-CoV-2 mRNA vaccination in patients with paroxysmal nocturnal hemoglobinuria

Yuya Kamura, Tatsuhiro Sakamoto, Yasuhisa Yokoyama, Hidekazu Nishikii, Mamiko Sakata-Yanagimoto, Shigeru Chiba, Naoshi Obara

Summary: This study reports on the incidence of hemolysis induced by SARS-CoV-2 mRNA vaccines in patients with paroxysmal nocturnal hemoglobinuria (PNH). The use of complement inhibitors in PNH patients was found to reduce the occurrence of hemolytic reactions following vaccination.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2022)

Add to Collection

Letter Oncology

Novel translocation of POGZ/STK11 in de novo mast cell leukemia with KIT D816H mutation

Kantaro Ishitsuka, Yuki Yoshizawa, Hidekazu Nishikii, Manabu Kusakabe, Yufu Ito, Yukinori Inadome, Tatsuhiro Sakamoto, Takayasu Kato, Naoki Kurita, Yasuhisa Yokoyama, Naoshi Obara, Yuichi Hasegawa, Yasuhito Nannya, Seishi Ogawa, Mamiko Sakata-Yanagimoto, Shigeru Chiba

LEUKEMIA & LYMPHOMA (2022)

Add to Collection

Article Medicine, General & Internal

Cardiac Tamponade as a Recurrence of Angioimmunoblastic T-Cell Lymphoma with the Detection of a p.Gly17Val RHOA Mutation in the Pericardial Effusion

Yuri Tsuboi, Yumoe Iimura, Fumiaki Matsumura, Toru Nanmoku, Sakurako Suma, Ryota Matsuoka, Tomoki Nakagawa, Daishi Nakagawa, Yasuhito Suehara, Keiichiro Hattori, Kimi Sato, Yumiko Maruyama, Tatsuhiro Sakamoto, Yasuhisa Yokoyama, Takayasu Kato, Naoki Kurita, Hidekazu Nishikii, Naoshi Obara, Masaki Ieda, Shigeru Chiba, Mamiko Sakata-Yanagimoto

Summary: We report a case of AITL patient who experienced deterioration of the condition due to massive pericardial effusion one month after autologous transplantation. The patient was diagnosed with cardiac tamponade caused by AITL recurrence, identified by the presence of p.Gly17Val RHOA mutation and T-lineage cells with abnormal immunephenotype in the pericardial effusion. This case suggests that precision medicine approach by detecting the p.Gly17Val RHOA mutation is useful for AITL management.

INTERNAL MEDICINE (2023)

Add to Collection

Letter Oncology

The fatty acid elongase Elovl6 is crucial for hematopoietic stem cell engraftment and leukemia propagation

Yusuke Kiyoki, Takayasu Kato, Sakura Kito, Takashi Matsuzaka, Shin Morioka, Junko Sasaki, Kenichi Makishima, Tatsuhiro Sakamoto, Hidekazu Nishikii, Naoshi Obara, Mamiko Sakata-Yanagimoto, Takehiko Sasaki, Hitoshi Shimano, Shigeru Chiba

LEUKEMIA (2023)

Add to Collection

Article Hematology

Repeated immunosuppressive rabbit antithymocyte globulin therapy for adult patients with relapsed or refractory aplastic anemia

Tatsuhiro Sakamoto, Naoshi Obara, Yumiko Maruyama, Takayasu Kato, Naoki Kurita, Keiichiro Hattori, Yasuhito Suehara, Hidekazu Nishikii, Yasuhisa Yokoyama, Mamiko Sakata-Yanagimoto, Kensuke Usuki, Shigeru Chiba

Summary: A retrospective evaluation of 19 patients with relapsed or refractory aplastic anemia who received first-line rATG treatment in two centers between 2009 and 2020 revealed that IST2-rATG is effective and safe in treating this disease.

EUROPEAN JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Article Oncology

Tumor heterogeneity and immune-evasive T follicular cell lymphoma phenotypes at single-cell resolution

Sakurako Suma, Yasuhito Suehara, Manabu Fujisawa, Yoshiaki Abe, Keiichiro Hattori, Kenichi Makishima, Tatsuhiro Sakamoto, Aya Sawa, Hiroko Bando, Daisuke Kaji, Takeshi Sugio, Koji Kato, Koichi Akashi, Kosei Matsue, Joaquim Carreras, Naoya Nakamura, Ayako Suzuki, Yutaka Suzuki, Ken Ito, Hiroyuki Shiiba, Shigeru Chiba, Mamiko Sakata-Yanagimoto

Summary: T follicular helper (TFH) cell lymphomas (TFHLs) exhibit remarkable tumor-cell heterogeneity and immune evasion characteristics, potentially playing important roles in treatment resistance.

LEUKEMIA (2023)

Add to Collection

Meeting Abstract Biophysics

Safety proof of romiplostim immediately after cord-blood transplantation: Results of a phase 1 trial

N. Kurita, Y. Maruyama, Y. Suehara, K. Hattori, T. Sakamoto, T. Kato, Y. Yokoyama, N. Obara, K. Maruo, K. Hashimoto, M. Sakata-Yanagimoto, H. Nishikii, S. Chiba

BONE MARROW TRANSPLANTATION (2022)

Add to Collection

Article Hematology

Administration of brentuximab vedotin to a Hodgkin lymphoma patient with liver dysfunction due to vanishing bile duct syndrome resulting in a partial response without any severe adverse events

Kantaro Ishitsuka, Yasuhisa Yokoyama, Naoko Baba, Ryota Matsuoka, Noriaki Sakamoto, Tatsuhiro Sakamoto, Manabu Kusakabe, Takayasu Kato, Naoki Kurita, Hidekazu Nishikii, Mamiko Sakata-Yanagimoto, Naoshi Obara, Yuichi Hasegawa, Shigeru Chiba

Summary: Vanishing bile duct syndrome (VBDS) is a rare hepatic disorder with no specific treatment. We treated a patient with classic Hodgkin lymphoma (HL) and VBDS using brentuximab vedotin (BV), achieving a partial metabolic response. Our experience suggests BV could be a treatment option for classic HL with VBDS.

JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.